Teva Pharmaceuticals and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid® 1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.
Teva Pharmaceuticals and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid® 1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.